

NCTR PROTOCOL E0219001

**TWO YEAR CHRONIC TOXICOLOGY STUDY OF BISPHENOL A (BPA) [CAS # 80-05-7]
ADMINISTERED BY GAVAGE TO SPRAGUE-DAWLEY RATS (NCTR) FROM GESTATIONAL DAY 6
UNTIL BIRTH AND DIRECTLY TO F₁ PUPS FROM POSTNATAL DAY (PND) 1; CONTINUOUS AND
STOP DOSE (PND 21) EXPOSURES**

STATISTICAL REPORT

STATISTICAL ANALYSIS OF INTERIM SACRIFICE SPERM PARAMETER DATA

**PREPARED
BY**

**BETH E. JULIAR
DIVISION OF BIOINFORMATICS AND BIOSTATISTICS**

FOR

**NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH
3900 NCTR ROAD
JEFFERSON, ARKANSAS 72079**

Signatures

Report prepared by Statistician:

Date

Beth E. Juliar, M.A., M.S., Division of Bioinformatics and Biostatistics/NCTR/FDA

Report reviewed by Statistician:

Date

Paul Felton, M.S., Division of Bioinformatics and Biostatistics /NCTR/FDA

Statistical Team Leader:

Date

Paul Felton, M.S., Division of Bioinformatics and Biostatistics /NCTR/FDA

Table of Contents

1. Objectives	1
1.1 Project Objectives	1
1.2 Analysis Objectives	1
2. Experimental Design.....	1
3. Statistical Methods.....	1
References.....	2
4. Results.....	2
4.1 BPA Treatments in the Stop Dose Arm.....	2
4.2 BPA Treatments in the Continuous Dose Arm.....	2
4.3 EE ₂ Treatments in the Continuous Dose Arm	3
5. Conclusions.....	3
Appendices.....	4
A. Statistical Tables	4
a) BPA Treatments in the Stop Dose Arm.....	5
b) BPA Treatments in the Continuous Dose Arm.....	7
c) EE ₂ Treatments in the Continuous Dose Arm	9
B. Data	11
Quality Control	12

Statistical Analysis of Interim Sacrifice Sperm Parameter Data

1. Objectives

1.1 Project Objectives

The goal of this two year chronic study is to characterize the long term toxicity of orally administered BPA, including developmental exposure, in the NCTR Sprague-Dawley (CD) rat over a broad dose range.

1.2 Analysis Objectives

The goal of this analysis is to evaluate the effects of exposure to BPA in Sprague-Dawley rats based on sperm parameters from the one year interim sacrifice animals.

2. Experimental Design

The study design consisted of first generation female and male rats (F₀) for up to 600 mating pairs randomized to treatment groups in 5 litters. The goal of the F₀ matings was to obtain 352 study litters, 50 per dose group for vehicle controls and five BPA dose groups, 2.5, 25, 250, 2500, and 25000 µg/kg bw/day, and 26 for each of two EE₂ dose groups, 0.05 and 0.5 µg/kg bw/day. Dams were dosed daily from gestation day (GD) 6 until parturition. Dosing was by gavage for F₀ dams and F₁ pups, the second study generation. Litters were culled to 10 pups on PND 1. There were two study dosing arms of F₁ animals, daily continuous dosing to termination, and daily dose stopped at post-natal day (PND) 21. There was a vehicle control group and five BPA groups for each study dosing arm, and EE₂ daily dose groups for the continuous dosing arm only. From the F₁ litters, pups were allocated at weaning, PND 21, to the interim (1 year) and terminal (2 year) sacrifices for the core study. For vehicle and BPA terminal sacrifice groups, there were 50 pups each; for the interim sacrifice and the EE₂ terminal sacrifice groups, there were 20-26 pups each. Pups within litter and sex were assigned to different dosing arms and sacrifice times.

Sperm Parameters Data

For the one year interim sacrifice males, the left testis was to be used for evaluation of testicular spermatid head counts, and the left epididymis was to be used for epididymal sperm counts, morphology, and motility evaluations.

3. Statistical Methods

Statistical analyses and comparisons were conducted separately by compound and dosing regimen: vehicle control and BPA treatments in the stop dose arm; vehicle control and BPA treatments in the continuous dose arm; and vehicle control and EE₂ treatments in the continuous dose arm. Analysis of sperm morphology data was performed using a generalized linear model with a Poisson distribution and a log link function. Each treatment was compared to the vehicle control group, and adjustment for multiple comparisons was performed using Dunnett's method. Percent sperm motility, testes sperm counts, and cauda sperm counts were analyzed using an ANOVA model with Kenward-Roger estimated degrees of freedom (Kenward and Roger, 1997). Each treatment was compared to the control group, and adjustment for multiple comparisons was performed using Dunnett's method. Tests of trend, increasing treatment effect with increasing dose, were performed for each compound and dosing regimen. Tests were conducted as two-sided at the 0.05 significance level.

For each sperm endpoint, a sensitivity analysis was also performed. During initial preweaning of animals, 60 core study 1 year interim sacrifice males with sperm data (8 in vehicle control, 40 in BPA 2.5, 25, 250, 2500, and 25000 $\mu\text{g}/\text{kg}$ bw/day, and 12 in EE₂ $\mu\text{g}/\text{kg}$ bw/day dose groups) were held in the same rooms as a special BPA 250,000 $\mu\text{g}/\text{kg}$ bw/day high dose requested by an academic laboratory. In consultation with the Principal Investigator, to address the possibility of inadvertent exposure of the core study animals, a sensitivity analysis excluding these 60 males was also performed to test the robustness of the results. Additional statistically significant pairwise comparisons from the sensitivity analysis are reported in the text.

References

Kenward, M. G. and Roger, J. H. (1997), "Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood," *Biometrics* **53**:983–997.

4. Results

Tables are included in Appendix A.

4.1 BPA Treatments in the Stop Dose Arm

Counts and percentages for sperm morphology are given in Table 1 for BPA treatments in the stop dose arm. Analysis results for sperm morphology are given in Table 3. Only five animals total in BPA 25, 250 and 2500 $\mu\text{g}/\text{kg}$ bw/day treatment groups had sperm head abnormalities, and there were no significant results for comparisons of treatments to the vehicle control. For sperm tail abnormalities and total abnormalities, there were no statistically significant differences for any BPA treatment compared to the vehicle control.

Summary statistics for percent sperm motility, cauda sperm counts, and testes sperm counts are presented in Table 2. ANOVA results from analysis of treatment effect for percent motility, cauda counts, and testes counts are presented in Table 4. There were no statistically significant trends or differences for treatment groups compared to the control. Because of unequal variance across treatment groups for sperm testes counts identified using Levene's test, a nonparametric analysis was also conducted, but there was no difference in conclusions.

There were no statistically significant results in the sensitivity analyses for any sperm endpoint in the stop dose BPA arm.

4.2 BPA Treatments in the Continuous Dose Arm

Counts and percentages for sperm morphology are given in Table 5 for BPA treatments in the continuous dose arm. Analysis results for sperm morphology are given in Table 7. There were no significant results for comparisons of treatments to the vehicle control for sperm head, tail, or total abnormalities.

Summary statistics for percent sperm motility, cauda sperm counts, and testes sperm counts are presented in Table 6. ANOVA results from analysis of treatment effect for percent motility, cauda counts, and testes counts are presented in Table 8. There were no statistically significant trends or differences for treatment groups compared to the vehicle control.

There were no statistically significant results in the sensitivity analyses for any sperm endpoint in the continuous dose BPA arm.

4.3 *EE₂ Treatments in the Continuous Dose Arm*

Counts and percentages for sperm morphology are given in Table 9 for EE₂ treatments in the continuous dose arm. Analysis results for sperm morphology are given in Table 11. There were no significant results for comparisons of treatments to the vehicle control for sperm head, tail, or total abnormalities.

Summary statistics for percent sperm motility, cauda sperm counts, and testes sperm counts are presented in Table 10. ANOVA results from analysis of treatment effect for percent motility, cauda counts, and testes counts are presented in Table 12. There were no statistically significant trends or differences for treatment groups compared to the vehicle control.

There were no statistically significant results in the sensitivity analyses for any sperm endpoint in the continuous dose EE₂ arm.

5. *Conclusions*

In both the stop dose and the continuous dose arms, there were no significant results in analysis of BPA or EE₂ treatments compared to the vehicle control for sperm head, tail, or total abnormalities. In analyses of percent sperm motility, cauda sperm counts and testes sperm counts, there were no statistically significant differences for BPA or EE₂ treatment groups compared to the vehicle control in the stop dose or continuous dose arm.

Appendices

A. Statistical Tables

a) *BPA Treatments in the Stop Dose Arm*

**Table 1. Counts of Sperm Morphology
 Abnormality for Bisphenol-A Stop Dose ($\mu\text{g}/\text{kg}_{\text{BW}}/\text{day}$)**

Dose	Type	Abnormal		Percent
		Count	N (Animals)	
0	Head	0	20	100.0
	Tail	0	17	85.0
		1	3	15.0
	Total	0	17	85.0
		1	3	15.0
2.5	Head	0	20	100.0
	Tail	0	17	85.0
		1	3	15.0
	Total	0	17	85.0
		1	3	15.0
25	Head	0	17	89.5
		1	2	10.5
	Tail	0	16	84.2
		1	2	10.5
	Total	2	1	5.3
		0	15	78.9
		1	2	10.5
		2	2	10.5
250	Head	0	18	94.7
		1	1	5.3
	Tail	0	17	89.5
		1	2	10.5
Total	0	16	84.2	
		1	3	15.8
2500	Head	0	18	90.0
		1	2	10.0
	Tail	0	16	80.0
		1	4	20.0
Total	0	14	70.0	
		1	6	30.0
25000	Head	0	22	100.0
	Tail	0	22	100.0
	Total	0	22	100.0

Table 2. Summary Statistics of Sperm Outcomes for Bisphenol-A Stop-Dose ($\mu\text{g}/\text{kg}_{\text{BW}}/\text{day}$)

Outcome	0			2.5			25			250			2500			25000		
	N	Mean	SE	N	Mean	SE	N	Mean	SE	N	Mean	SE	N	Mean	SE	N	Mean	SE
Cauda Counts	20	1059.1	86.6	20	1185.5	83.3	19	1016.7	65.5	19	1111.3	66.1	20	1020.3	89.1	22	1015.6	81.1
Percent Motility	20	74.8	4.3	20	75.8	2.3	19	72.4	3.4	19	70.2	4.2	20	67.9	5.6	22	77.7	2.2
Testes Counts	20	76.5	9.4	20	77.7	4.8	19	72.2	5.3	19	72.5	6.3	20	73.6	9.0	22	75.8	4.7

Table 3. Poisson Regression of Sperm Morphology Abnormality Counts Per Animal for Bisphenol-A Stop Dose ($\mu\text{g}/\text{kg}\cdot\text{BW}/\text{day}$)

Abnormality	0			2.5			25			250			2500			25000		
	Mean ²	SE	Trend	Mean	SE	P	Mean	SE	P									
Total	0.15	0.09	0.970	0.15	0.09	1.000	0.32	0.13	0.748	0.16	0.09	1.000	0.30	0.12	0.795	0.00	0.00	1.000
Head	0.00	0.00	0.993	0.00	0.00	1.000	0.11	0.07	1.000	0.05	0.05	1.000	0.10	0.07	1.000	0.00	0.00	1.000
Tail	0.15	0.09	0.969	0.15	0.09	1.000	0.21	0.11	0.992	0.11	0.07	0.996	0.20	0.10	0.996	0.00	0.00	1.000

¹ All p-values for dose comparisons are relative to control and were adjusted using Dunnett's method.

² Mean counts and standard errors were estimated using Poisson analysis.

Table 4. ANOVA Comparison of Least Squares Mean Sperm Outcomes for Bisphenol-A Stop Dose ($\mu\text{g}/\text{kg}\cdot\text{BW}/\text{day}$)¹

Outcome	0			2.5			25			250			2500			25000		
	Mean	SE	Trend	Mean	SE	P												
Percent Sperm Motility	74.8	3.8	0.725	75.8	3.8	1.000	72.4	3.9	0.991	70.2	3.9	0.872	67.9	3.8	0.581	77.7	3.7	0.974
Cauda Sperm Counts	1059.1	79.7	0.348	1185.5	79.7	0.690	1016.7	81.8	0.996	1111.3	81.8	0.989	1020.3	79.7	0.997	1015.6	76.0	0.994
Testes Sperm Counts	76.5	6.8	0.786	77.7	6.8	1.000	72.2	7.0	0.990	72.5	7.0	0.993	73.6	6.8	0.998	75.8	6.5	1.000

¹ All p-values for dose comparisons are relative to the control group and were adjusted using Dunnett's method.

b) BPA Treatments in the Continuous Dose Arm

**Table 5. Counts of Sperm Morphology
Abnormality for Bisphenol-A Continuous Dose ($\mu\text{g}/\text{kg}_{\text{BW}}/\text{day}$)**

Dose	Type	Abnormal		Percent
		Count	N (Animals)	
0	Head	0	18	100.0
	Tail	0	15	83.3
		1	3	16.7
	Total	0	15	83.3
1		3	16.7	
2.5	Head	0	21	95.5
		1	1	4.5
	Tail	0	15	68.2
		1	6	27.3
		2	1	4.5
	Total	0	14	63.6
1		7	31.8	
2		1	4.5	
25	Head	0	17	94.4
		1	1	5.6
	Tail	0	15	83.3
		1	3	16.7
	Total	0	15	83.3
		1	2	11.1
		2	1	5.6
250	Head	0	22	91.7
		1	2	8.3
	Tail	0	22	91.7
		1	2	8.3
	Total	0	20	83.3
		1	4	16.7
2500	Head	0	16	88.9
		1	2	11.1
	Tail	0	16	88.9
		1	2	11.1
	Total	0	14	77.8
		1	4	22.2
25000	Head	0	21	100.0
	Tail	0	18	85.7
		1	3	14.3
	Total	0	18	85.7
		1	3	14.3

Table 6. Summary Statistics of Sperm Outcomes for Bisphenol-A Continuous Dose ($\mu\text{g}/\text{kg}_{\text{BW}}/\text{day}$)

Outcome	0			2.5			25			250			2500			25000		
	N	Mean	SE	N	Mean	SE	N	Mean	SE	N	Mean	SE	N	Mean	SE	N	Mean	SE
Cauda Counts	18	990.8	78.0	22	999.3	87.7	18	1075.5	68.5	24	997.7	68.7	18	1061.9	51.0	21	1027.2	80.7
Percent Motility	18	65.9	4.6	22	64.0	5.1	18	72.4	3.1	24	66.7	4.5	18	69.9	3.4	21	69.4	4.2
Testes Counts	18	83.4	9.5	22	76.8	7.7	18	88.5	6.1	24	81.5	6.8	18	85.1	7.1	21	76.6	6.0

Table 7. Poisson Regression of Sperm Morphology Abnormality Counts Per Animal for Bisphenol-A Continuous Dose ($\mu\text{g}/\text{kg}\cdot\text{BW}/\text{day}$)¹

Abnormality	0			2.5			25			250			2500			25000		
	Mean ²	SE	Trend	Mean	SE	P	Mean	SE	P									
Total	0.17	0.10	0.524	0.41	0.14	0.491	0.22	0.11	0.993	0.17	0.08	1.000	0.22	0.11	0.993	0.14	0.08	1.000
Head	0.00	0.00	0.999	0.05	0.05	1.000	0.06	0.06	1.000	0.08	0.06	1.000	0.11	0.08	1.000	0.00	0.00	1.000
Tail	0.17	0.10	0.299	0.36	0.13	0.666	0.17	0.10	1.000	0.08	0.06	0.907	0.11	0.08	0.990	0.14	0.08	1.000

¹ All p-values for dose comparisons are relative to control and were adjusted using Dunnett's method.

² Mean counts and standard errors were estimated using Poisson analysis.

Table 8. ANOVA Comparison of Least Squares Mean Sperm Outcomes for Bisphenol-A Continuous Dose ($\mu\text{g}/\text{kg}\cdot\text{BW}/\text{day}$)¹

Outcome	0			2.5			25			250			2500			25000		
	Mean	SE	Trend	Mean	SE	P	Mean	SE	P	Mean	SE	P	Mean	SE	P	Mean	SE	P
Percent Sperm Motility	65.9	4.6	0.425	64.0	4.2	0.998	72.4	4.6	0.769	66.7	4.0	1.000	69.9	4.6	0.956	69.4	4.3	0.971
Cauda Sperm Counts	990.8	79.2	0.647	999.3	71.7	1.000	1075.5	79.2	0.904	997.7	68.6	1.000	1061.9	79.2	0.950	1027.2	73.3	0.997
Testes Sperm Counts	83.4	7.7	0.789	76.8	7.0	0.950	88.5	7.7	0.986	81.5	6.7	1.000	85.1	7.7	1.000	76.6	7.1	0.944

¹ All p-values for dose comparisons are relative to the control group and were adjusted using Dunnett's method.

c) *EE₂ Treatments in the Continuous Dose Arm*

**Table 9. Counts of Sperm Morphology
 Abnormality for Ethinyl Estradiol Dose ($\mu\text{g}/\text{kg}\cdot\text{BW}/\text{day}$)**

<i>Dose</i>	<i>Type</i>	<i>Abnormal</i>		<i>Percent</i>
		<i>Count</i>	<i>N (Animals)</i>	
0	Head	0	18	100.0
	Tail	0	15	83.3
		1	3	16.7
	Total	0	15	83.3
1		3	16.7	
0.05	Head	0	17	77.3
		1	5	22.7
	Tail	0	17	77.3
		1	5	22.7
	Total	0	14	63.6
		1	6	27.3
		2	2	9.1
0.5	Head	0	22	95.7
		1	1	4.3
	Tail	0	21	91.3
		1	1	4.3
		2	1	4.3
	Total	0	20	87.0
1		2	8.7	
		2	1	4.3

**Table 10. Summary Statistics of Sperm Outcomes
 for Ethinyl Estradiol Dose ($\mu\text{g}/\text{kg}\cdot\text{BW}/\text{day}$)**

<i>Outcome</i>	<i>0</i>			<i>0.05</i>			<i>0.5</i>		
	<i>N</i>	<i>Mean</i>	<i>SE</i>	<i>N</i>	<i>Mean</i>	<i>SE</i>	<i>N</i>	<i>Mean</i>	<i>SE</i>
Cauda Counts	18	990.8	78.0	22	891.7	71.6	23	856.9	53.1
Percent Motility	18	65.9	4.6	22	67.2	4.8	23	70.8	2.7
Testes Counts	18	83.4	9.5	22	70.0	4.7	23	73.7	4.5

Analysis of Interim Sacrifice Sperm Parameters

Table 11. Poisson Regression of Sperm Morphology Abnormality Counts Per Animal for Ethinyl Estradiol Dose ($\mu\text{g}/\text{kg}_{\text{BW}}/\text{day}$)¹

Abnormality	0			0.05			0.5		
	Mean ²	SE	P	Mean	SE	P	Mean	SE	P
Total	0.17	0.10	0.213	0.45	0.14	0.213	0.17	0.09	0.997
Head	0.00	0.00	0.972	0.23	0.10	0.972	0.04	0.04	0.976
Tail	0.17	0.10	0.873	0.23	0.10	0.873	0.13	0.08	0.934

¹ All p-values for dose comparisons are relative to control and were adjusted using Dunnett's method.

² Mean counts and standard errors were estimated using Poisson analysis.

Table 12. ANOVA Comparison of Least Squares Mean Sperm Outcomes for Ethinyl Estradiol Dose ($\mu\text{g}/\text{kg}_{\text{BW}}/\text{day}$)¹

Outcome	0			0.05			0.5		
	Mean	SE	P	Mean	SE	P	Mean	SE	P
Percent Sperm Motility	65.9	4.4	0.968	67.2	4.0	0.968	70.8	3.9	0.617
Cauda Sperm Counts	990.8	72.3	0.487	891.7	65.4	0.487	856.9	64.0	0.282
Testes Sperm Counts	83.4	6.7	0.239	70.0	6.0	0.239	73.7	5.9	0.445

¹ All p-values for dose comparisons are relative to the control group and were adjusted using Dunnett's method.

B. Data

Sperm parameter data were provided in an Excel spreadsheet from the Principal Investigator.

Quality Control

1. *Data Verification*

The extraction of the data into SAS was verified by the reviewer, Paul Felton, by review of the SAS code used to extract and verify the data.

2. *Computer Program Verification*

SAS programs were used to extract the data, explore the distributional properties of the data, and perform the statistical analysis.

The SAS programs were verified by detailed review of the program code, the program log, and the program output.

3. *Statistical Report Review*

3.1 *Statistical Report Text*

The statistical report was reviewed for logic, internal completeness, technical appropriateness, technical accuracy, and grammar. Technical appropriateness was reviewed based on statistical expertise.

Comments and questions were provided from the reviewer to the statistician. The statistician made appropriate changes and returned the report to the reviewer for final verification.

The text of the final statistical report was considered by the reviewer to be logical, internally complete, and technically appropriate and accurate. The statistical results stated in the text accurately presented those in the tables.

3.2 *Table Verification*

Analysis results were output from SAS to an .rtf file using PROC REPORT, which were then copied into the statistical report.

Statistical report tables were verified by checking the procedure used to create the tables and, additionally, by checking numbers sufficiently to conclude that the tables are correct.

4. *Conclusions*

The final statistical report has been fully reviewed and is considered by the reviewer to be logical, internally complete, and technically appropriate and accurate.